|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using quantitative real-time polymerase chain reaction, we found a significant upregulation of AR and PSA mRNA expression in CaP comparison to BPH.
|
22731640 |
2012 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Receiver-operating characteristic curve (ROC) revealed that miR-145 in UEVs combined with serum PSA could differentiate PCa from BPH better than PSA alone (AUC 0.863 and AUC 0.805, respectively).
|
28617988 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently prostate-specific antigen is used for prostate cancer (PCa) screening, however it lacks the necessary specificity for differentiating PCa from other diseases of the prostate such as benign prostatic hyperplasia (BPH), presenting a clinical need to distinguish these cases at the molecular level.
|
29695737 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The mRNA PSA expression in needle biopsy material did not seem to be related to PSA circulating levels in prostate cancer patients (r = 0.281), whereas in BPH patients the two parameters correlated significantly (r = 0.667, p < 0.01).
|
12705330 |
2003 |
|
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results indicate that allelic variation in PSA promoter activity may be androgen dependent and interaction of genes in androgen pathway may influence the risk of BPH and PC in Singapore males.
|
18495332 |
2008 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of Trigonella foenum-graecum extract on prostate-specific antigen, and prostate function in otherwise healthy men with benign prostate hyperplasia.
|
31828857 |
2020 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) lacks specificity and sensitivity in discriminating prostate cancer (PCa) from benign prostatic hyperplasia (BPH) when the total PSA (tPSA) level is between 4 and 10 ng/mL.
|
26954072 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP19 1531 C>T, SRD5A2 gene V89L, CYP17 gene -34 T/C, PSA-158 (G/A) regions were evaluated for the association between polymorphisms and benign prostatic hyperplasia and prostate cancer in study population.
|
26214411 |
2015 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, the protein expressions of AR, 5AR2, and PSA were significantly lower in the PE gavaged group than BPH group in prostate tissue.
|
31591335 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumor doubling times were overestimated in patients with large volume benign prostatic hyperplasia since hyperplasia increases serum PSA, albeit 12 times less than cancer.
|
7685704 |
1993 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We first profiled global serum miRNAs in a pilot set of PCa and benign prostatic hyperplasia (BPH) cases undergoing TRUS-guided prostate biopsy due to elevated PSA levels.
|
31534967 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PSA level was significantly higher in the PCa group than in BPH (18.2 versus 9 ng/mL, <i>p</i> < 0.01), while volume of prostate gland was significantly higher in the BPH group than in PCa (39.1 versus 31.1 cm<sup>3</sup>, <i>p</i> = 0.02).
|
30186533 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
PSA showed high immunoexpression in all BPH patients and a focal positivity in Ser-Se-Ly treated patients after 3 months.
|
28327526 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, effects of the 14 SNPs on BPH related clinical traits, including International Prostate Symptom Score (IPSS), prostate volume, total PSA, and free PSA were evaluated using linear regression analysis.
|
23620269 |
2013 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals.
|
31569672 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
As BPH-related factors, International Prostate Symptom Score, quality of life, maximal flow rate, postvoid residual volume, prostate-specific antigen, prostate volume, prostate calculi, and medication state for BPH were investigated.
|
31734054 |
2020 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
With the more sensitive nanoparticle-based lectin-immunoassay we detected a statistically significant increase in the PSA fucosylation in PCa tissue compared to benign tissue (p=0.001) and in urine from PCa patients compared to BPH patients (p=0.030), and an even greater discrimination (p=0.010) when comparing BPH patients to PCa patients with Gleason score≥7.
|
27818346 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, at a fixed specificity of 95%, the sensitivity of tPSA was 19% and that of the fPSA/tPSA ratio was 40% in distinguishing PCa from BPH.
|
10792086 |
2000 |
|
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PSA-158G/A polymorphism may be an inhibitor to the incidence of BPH in Caucasians, but it is likely to be a susceptible factor in Asians.
|
28430620 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have used a reverse transcription-PCR assay for prostate-specific antigen mRNA and an immunocytochemical staining method for cytokeratins to test this hypothesis in paired peripheral blood (PB) and bone marrow (BM) specimens from 71 patients with clinically localized disease before radical prostatectomy, 14 patients with advanced-stage carcinoma of the prostate, and 30 controls (young healthy volunteers, patients without prostate disease, and patients with benign prostatic hyperplasia).Controls were negative in BM and PB.
|
9815680 |
1997 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study was to determine whether PSCA mRNA positivity in preoperatively negative prostatic biopsy samples from BPH men with PSA > 4.0 ng/ml and/or suspicious DRE findings had predictive performance following TURP.
|
19462463 |
2009 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found a significantly higher PSA/GG distribution in PC (30%) than either benign prostatic hyperplasia (BPH) (18%) or population controls (16%) (P = 0.025).
|
15599941 |
2005 |
|
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, CAG and GGC repeats in the AR and PSA gene polymorphisms may be associated with prostate cancer risk and BPH in the Turkish population.
|
22653589 |
2012 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum PSA concentrations were markedly elevated in BPH and Pca patients compared to control subjects.
|
21986563 |
2012 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
All patients with BPH were divided into two groups according to international prostate symptom score (IPSS), prostate specific antigen (PSA) level, Q(max), and prostate volume.
|
21532858 |
2011 |